Soligenix, Inc. SNGX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -73.04%
- 1 year
- -76.70%
- Open
- 0.368
- Prev close
- 0.3559
- Mkt cap
- 7.86M
- Vol
- 137.41K
- Avg vol
- 194.07K
- EPS
- -0.80
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.355
- High
- 0.3699
- Forward P/E
- -0.56
- Beta
- 0.00
- Short ratio
- 1.06
- Inst. own
- 2.63%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.49
- 200-d avg
- 4.98
- 1y target
- 22.50
News
2 months ago defenseworld.net
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)
Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses…
-
2 months ago benzinga.com
Soligenix Q2 EPS $(0.12) Beats $(0.15) Estimate
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 85.37 percent increase over losses of $(0.82) per…
2 months ago prnewswire.com
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare…
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Friday's after-market session. The market value of their outstanding shares is at $12.7 million. iTonic…
4 months ago feeds.newsfilecorp.com
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors
-
4 months ago benzinga.com
Soligenix To Apply For Bundibugyo Ebola Vaccine Development Funding
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
4 months ago prnewswire.com
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, Inc.…
-
5 months ago benzinga.com
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
5 months ago benzinga.com
Why Tetra Technologies Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket
Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100M stock offering. XOS, Wellchange, and J-Star are top gainers while Jianzhi, NRx, and Volato are…
5 months ago benzinga.com
Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results
U.S. stocks traded mixed, Nasdaq down 0.3%. Dow up 0.59%, S&P 500 down 0.09%. Consumer discretionary shares up 1.9%. Dycom Industries reports strong earnings.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
5 months ago benzinga.com
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results
US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, energy down 1.9%. DKS stock falls 5% on mixed results.
5 months ago benzinga.com
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
5 months ago benzinga.com
Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus
Soligenix shares surged 72.32% in after-hours trading following rapid Bundibugyo virus vaccine development announcement.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 months ago prnewswire.com
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Soligenix, Inc.…
-
5 months ago benzinga.com
U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide
https://www.cdc.gov/ebola/situation-summary/index.html
-
5 months ago benzinga.com
Soligenix Q1 EPS $(0.28), Inline
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 73.58 percent increase over losses of $(1.06) per share from the same period…
5 months ago prnewswire.com
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 months ago benzinga.com
Crude Oil Gains Over 3%; General Motors Earnings Top Views
US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0.65%. GM reports better-than-expected Q1 results.
6 months ago benzinga.com
Why Is Soligenix Stock Sinking Tuesday?
Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.
6 months ago benzinga.com
Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings
US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63%,…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
6 months ago benzinga.com
The Data Monitoring Committee Recommends Soligenix To Halt Phase 3 FLASH2 Trial Of HyBryte (Synthetic Hypericin) For Cutaneous T-cell lymphoma For Futility
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
6 months ago prnewswire.com
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
-
7 months ago benzinga.com
Soligenix Announces Publication Of Comparability Study Results Evaluating HyBryte Versus Valchlor For Treatment Of Cutaneous T-Cell Lymphoma In Oncology And Therapy
HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX)…
7 months ago prnewswire.com
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor ® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)…
-
7 months ago benzinga.com
Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.56) by 48.75 percent. This is a 74.82 percent increase over losses of $(1.14)…
7 months ago prnewswire.com
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026 from HyBryte™ trial PRINCETON, N.J., March 31, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)…
-
7 months ago benzinga.com
Soligenix Secures EU Orphan Drug Status For Rare Disease Treatment, Designation Provides 10-Year Market Exclusivity And Development Support
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
7 months ago prnewswire.com
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
7 months ago prnewswire.com
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Highlighting Positive Results in Comparison to Valchlor ® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
7 months ago globenewswire.com
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
AUSTIN, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce…
-
7 months ago benzinga.com
Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs
Expert Opinion on Investigational Drugs is an international monthly peer-reviewed journal, evaluating drugs in preclinical and clinical development. Authors are encouraged to express their Expert…
7 months ago prnewswire.com
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
-
7 months ago benzinga.com
Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03122026_SNGX_Bautz.pdf
-
7 months ago benzinga.com
Soligenix's SGX945 (Dusquetide) Receives Promising Innovative Medicine Designation In U.K. For Behçet's Disease
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
7 months ago prnewswire.com
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
PRINCETON, N.J., March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
8 months ago prnewswire.com
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
8 months ago prnewswire.com
Soligenix to Present at BIO Investment & Growth Summit
PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
8 months ago prnewswire.com
Soligenix Details Recent Progress and Upcoming Milestones
PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to…
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
9 months ago defenseworld.net
Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5%
Soligenix Inc. (NASDAQ: SNGX - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 454,993 shares, a…
-
9 months ago benzinga.com
Soligenix Enters $3.45M At-The-Market Equity Sales Agreement With Rodman & Renshaw
Item 8.01.Other Events. On January 23, 2026, Soligenix, Inc. (the "Company") and Rodman & Renshaw, LLC ("Rodman") entered into an At Market Issuance Sales Agreement (as amended, the "Sales…
-
10 months ago benzinga.com
Soligenix Announces Results From Phase 2a Proof Of Concept Study Evaluating SGX945 In Treatment Of Behçet's Disease Published In Rheumatology (Oxford)
Study results support advancing SGX945 in this difficult-to-treat orphan diseaseResults suggest potential durability of response for maintenance therapyPRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ --…
10 months ago prnewswire.com
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J. , Dec. 18, 2025 /PRNewswire/…